MAPT and hippocampal atrophy: These biomarkers include episodic memory decline, hippocampal atrophy on MRI, abnormal cerebrospinal fluid (CSF) biomarkers (e.g., low amyloid-β42, increased tau), and abnormal PET scan results showing amyloid and tau deposits or reduced glucose metabolism in temporoparietal regions (Armananzas et al., 2013; Sarraf et al., 2016; Schirrmeister et al., 2017; Leandrou et al., 2018).